Breathe easier with Anoro® Ellipta®
19 July 2016
Kuala Lumpur, 19 July 2016: An estimated 500,000 Malaysians are suffering from chronic obstructive pulmonary disease, otherwise known as COPD. The condition is not curable but highly manageable. In an effort to provide an improved and more convenient method of treatment for COPD patients, GlaxoSmithKline Malaysia today launched Anoro® Ellipta®, a once-daily dual medication for patients suffering from COPD. Anoro® Ellipta® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients suffering from the disease.
Anoro® Ellipta® is a combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist and vilanterol (VI), a long-acting beta2-adrenergic agonists. UMEC is a type of bronchodilator and VI relaxes the bronchial smooth muscle. Following oral inhalation, both compounds act locally on airways to produce bronchodilation through separate mechanisms, providing relief for those suffering from COPD.2
The condition is mainly caused by smoking and is characterised by progressive, partially reversible airflow obstruction and lung hyperinflation, all of which contribute to the severity of the disease. The most common symptoms of COPD are breathlessness (a “need for air”), excessive saliva and mucus in the airway and a chronic cough. As the condition worsens, simple activities, such as eating and walking can become a challenge, causing patients to lose weight and get weaker.3
Globally, the disease affects over 64 million people and 3 million have died of COPD. A prediction by World Health Organization (WHO) estimates that COPD will become the third leading cause of death worldwide by 2030.5Due to the prevalence of tobacco smoking and air pollution in Asia Pacific, incidences of COPD also continue to be on the rise. Unfortunately, many cases go unnoticed as the condition is often confused with asthma due to the similar symptoms.1
In Malaysia, COPD is ranked fifth in terms of disease burden and this is reflected in hospital admission rates for COPD attack. Although there are existing guidelines, they do not provide an organisational framework for managing patients. This then results in inconsistent application of clinical plans and different patient outcomes.7
“After over 10 years of design and development, we are proud to introduce Anoro® Ellipta® to the public today as an improved option to manage COPD. This development provides healthcare professionals with a new option to consider for appropriate COPD patients. GSK understands the importance of developing innovations that meet the different needs of patients. With Anoro® Ellipta®, patients will be able to better relieve their symptoms,” said Dr. Saikiran Leekha, Country Medical Director for GSK Malaysia and Brunei.
He added, “Due to our heritage of innovation, GSK has been one of the leaders in respiratory for over 45 years and we continue to develop and produce inhalers in an effort to improve the quality of life of our patients. GSK has a broad portfolio of respiratory treatments and we are focused on continuously developing treatment options that will enable people to do more, feel better and live longer.”
According to Professor Dato’ Dr Haji Abdul Razak Abdul Muttalif, Senior Consultant Chest Physician, “COPD is a growing health concern in the country. However, it is often misdiagnosed causing progression of the disease that significantly affects the daily lives of patients. The condition restrains them from doing simple activities, such as walking up the stairs and doing light exercises. Hence, effective management of the condition through better compliance is crucial in enhancing the quality of life. Together with GSK, we look forward to seeing patient adherence improve with the once-daily COPD medication.”
Anoro® Ellipta® has been shown to be generally well-tolerated. A study was conducted to examine the effectiveness of the inhaler found that participants reported high levels of satisfaction with the Anoro® Ellipta®, describing it as straightforward to operate. Ergonomic design, mouthpiece fit and dose counter visibility and ease of interpretation emerged as frequently cited drivers of preference for the Anoro® Ellipta® compared to other inhalers.8
# # #
About Anoro® Ellipta®
Anoro® Ellipta® is a once-daily dual bronchodilator treatment for adult patients with chronic obstructive pulmonary disease (COPD). It contains two compounds, umeclidinium (UMEC), a long-acting muscarinic antagonist and vilanterol (VI), a long-acting beta2 agonist. The approved dose of of UMEC/ VI is 62.5/25 micrograms once daily. Its safety profile and efficacy has been studied in a Phase III pivotal programme including seven clinical studies with almost 6,000 patients with COPD.
Respiratory Development Programmes
The GSK respiratory development portfolio includes LAMA/LABA (umeclidinium bromide (UMEC)/VI), VI monotherapy and MABA (GSK961081), developed in collaboration with Theravance, as well as GSK’s investigational medicines FF monotherapy, UMEC monotherapy and anti-IL5 MAb (mepolizumab). These investigational medicines are not currently approved anywhere in the world.
ANORO® ELLIPTA® is a trademark of the GlaxoSmithKline group of companies.
 The Malaysian Times, COPD squeezes one’s life, May 9 2014. Available from http://www.themalaysiantimes.com.my/copd-squeezes-ones-life/
 Anoro Ellipta Malaysia Prescribing Information, PI02MAL_01Mar2016.
 World Health Organization, Media centre, 2015. Available from http://www.who.int/mediacentre/factsheets/fs315/en/
 Regional COPD Working Group. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology 2009; 14:90-97
 BMC Pulmonary Medicine, Impact of clinical pathway on clinical outcomes in the management of COPD exacerbation, 2012. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479064/.
8 Svedsater, H., Dale P., Garrill K., Walker R. and Wopse M., BMC Pulmonary Medicine, Qualitative assessment of attributes and ease of use of the Ellipta dry powder inhaler for delivery of maintenance therapy for asthma and COPD, 2013.